Continuous subcutaneous injection of human insulin analog (Insulin Aspart) treats type 2 diabetes mellitus

The effect of continuous subcutaneous insulin injection (CSII) treatment in type 2 diabetic patients was observed. Forty-six cases and 42 cases were treated with Insulin Aspart (human insulin analogue) and Novolin R (human insulin) for 5 days, respectively. There was no difference in controlling blood glucose between two groups. Both Novolin R and Insulin Aspart during CSII treatment in type 2 diabetes were safe and efficient. The doses of Insulin Aspart were significantly lower than those of Novolin R, thus, it seems that the former was more efficient than the latter.